Trial Profile
A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Ifetroban (Primary)
- Indications Aspirin-induced asthma
- Focus Therapeutic Use
- Sponsors Cumberland Pharmaceuticals
- 16 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 03 May 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.
- 03 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.